Pulse Biosciences (Nasdaq : PLSE) February 2021 Forward-looking statements This presentation by Pulse Biosciences, Inc., contain estimates and forward-looking statements as of February 3, 2021 including, among others, statements regarding Pulse Biosciences' future business plans, products, commercial applications, intellectual property strategy, clinical trials, regulatory processes and pathways, and markets for its technologies, as well as patient and physician behavior and preferences and other future eve ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2020 Results Earnings Conference Call February 22, 2021 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Vice President at Gilmartin Group LLC Darrin Uecker - Chief Executive Officer, President, Director Ed Ebbers - Executive Vice President, General Manager of Dermatology Sandra Gardiner - Executive Vice President, Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Michael Fox - Park City Capital Operator ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2020 Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - Chief Executive Officer, President and Director Ed Ebbers - Executive Vice President and General Manager, Dermatology Sandra Gardiner - Executive Vice President and Chief Financial Office Conference Call Participants Sean Kang - H.C. Wainwright Operator Greeting and welcome to the Pulse Biosciences' Third Quarter 2020 Earnings Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bio ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q2 2020 Earnings Conference Call August 10, 2020 4:30 PM ET Company Participants Philip Taylor - IR Darrin Uecker - President, CEO Ed Ebbers - EVP and General Manager of Dermatology Sandy Gardiner - EVP and CFO Conference Call Participants Sean Kang - H.C. Wainwright Operator Thank you for standing by. This is the conference operator. Welcome to the Pulse Biosciences Second Quarter 2020 Earnings Conference Call. As a reminder, all participants are in a listen-only mode ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bioscien ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President and Chief Executive Officer Ed Ebbers - Executive Vice President and General Manager, Dermatology Sandy Gardiner - Executive Vice President and Chief Financial Officer Conference Call Participants Operator Greetings, and welcome to Pulse Biosciences First Quarter 2020 Earnings Call. At this time, all participants are in a listen-only ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 ___________________________________ Pulse Bioscien ...

Pulse Biosciences (Nasdaq : PLSE) March 2020 Forward-looking statements This presentation and accompanying oral presentation by Pulse Biosciences, Inc., contain estimates and forward-looking statements as of March 3, 2020 including, among others, statements regarding Pulse Biosciences' future business plans, products, commercial applications, clinical trials, regulatory processes and pathways, markets for its technologies, and other future events. You should not place undue reliance on forward-looking state ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2019 Earnings Conference Call March 16, 2020 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President and Chief Executive Officer Ed Ebbers - Executive Vice President and General Manager, Dermatology Sandy Gardiner - Executive Vice President and Chief Financial Officer Bob Duggan - Chairman Conference Call Participants Sean Kang - H.C. Wainwright Michael Fox - Park City Capital Operator Greetings, welcome to Pulse Biosciences Repor ...